12032199

Source:http://linkedlifedata.com/resource/pubmed/id/12032199

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0014822, umls-concept:C0017658, umls-concept:C0019004, umls-concept:C0024264, umls-concept:C0030705, umls-concept:C0086418, umls-concept:C0087111, umls-concept:C0205225, umls-concept:C0439165, umls-concept:C0443252, umls-concept:C0547047, umls-concept:C1332802, umls-concept:C1524112
pubmed:issue	6
pubmed:dateCreated	2002-5-28
pubmed:abstractText	Recombinant human erythropoietin (rHuEpo) may affect the human immune system. The aim of the study was to examine changes in CD4(+) and CD8(+) T-cell subpopulations, the expression of the inhibitory molecule, CD152 on T lymphocytes and the levels of interleukins (IL) 2, 6, 10, 12 and tumour necrosis factor alpha (TNF alpha) in primary glomerulonephritis chronic haemodialysis (HD) patients before and under rHuEpo treatment.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8706402
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD, http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation, http://linkedlifedata.com/resource/pubmed/chemical/CTLA-4 Antigen, http://linkedlifedata.com/resource/pubmed/chemical/CTLA4 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Cytokines, http://linkedlifedata.com/resource/pubmed/chemical/Erythropoietin, http://linkedlifedata.com/resource/pubmed/chemical/Ferritins, http://linkedlifedata.com/resource/pubmed/chemical/Hematinics, http://linkedlifedata.com/resource/pubmed/chemical/Immunoconjugates, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Transferrin, http://linkedlifedata.com/resource/pubmed/chemical/abatacept, http://linkedlifedata.com/resource/pubmed/chemical/epoetin alfa
pubmed:status	MEDLINE
pubmed:month	Jun
pubmed:issn	0931-0509
pubmed:author	pubmed-author:BrylEwaE, pubmed-author:Debska-Slizie?AlicjaA, pubmed-author:My?liwskaJolantaJ, pubmed-author:My?liwskiAndrzejA, pubmed-author:Racho?DominikD, pubmed-author:RutkowskiBoles?awB, pubmed-author:TrzonkowskiPiotrP
pubmed:issnType	Print
pubmed:volume	17
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1070-80
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:12032199-Anemia, pubmed-meshheading:12032199-Antigens, CD, pubmed-meshheading:12032199-Antigens, Differentiation, pubmed-meshheading:12032199-CD4-CD8 Ratio, pubmed-meshheading:12032199-CTLA-4 Antigen, pubmed-meshheading:12032199-Cytokines, pubmed-meshheading:12032199-Erythropoietin, pubmed-meshheading:12032199-Ferritins, pubmed-meshheading:12032199-Glomerulonephritis, pubmed-meshheading:12032199-Hematinics, pubmed-meshheading:12032199-Humans, pubmed-meshheading:12032199-Immunoconjugates, pubmed-meshheading:12032199-Lymphocyte Count, pubmed-meshheading:12032199-Lymphocytes, pubmed-meshheading:12032199-Middle Aged, pubmed-meshheading:12032199-Recombinant Proteins, pubmed-meshheading:12032199-Renal Dialysis, pubmed-meshheading:12032199-Time Factors, pubmed-meshheading:12032199-Transferrin
pubmed:year	2002
pubmed:articleTitle	Long-term therapy with recombinant human erythropoietin decreases percentage of CD152(+) lymphocytes in primary glomerulonephritis haemodialysis patients.
pubmed:affiliation	Department of Histology and Immunology, Medical University of Gda?sk, Gda?sk, Poland.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't